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Abstract The pinnacle of four decades of research, induced
pluripotent stem cells (iPSCs), and genome editing with the
advent of clustered, regularly interspaced, short palindromic
repeats (CRISPR) now promise to take drug development and
regenerative medicine to new levels and to enable the interro-
gation of disease mechanisms with a hitherto unimaginable
level of model fidelity. Autumn 2014 witnessed the first pa-
tient receiving iPSCs differentiated into retinal pigmented ep-
ithelium to treat macular degeneration. Technologies such as
3D bioprinting may now exploit these advances to manufac-
ture organs in a dish. As enticing as these prospects are, these
technologies demand a deeper understanding, which will lead
to improvements in their safety and efficacy. For example,
precise and more efficient reprogramming for iPSC produc-
tion is a requisite for wider clinical adoption. Improving
awareness of the roles of long non-coding RNAs (lncRNAs)
and microRNAs (miRNAs) and genomic epigenetic status
will contribute to the achievement of these aims. Similarly,
increased efficiency, avoidance of off-target effects, and ex-
pansion of available target sequences are critical to the uptake
of genome editing technology. In this review, we survey the
historical development of genetic manipulation and stem cells.
We explore the potential of genetic manipulation of iPSCs for
in vitro disease modeling, generation of new animal models,
and clinical applicability. We highlight the aspects that define
CRISPR-Cas as a breakthrough technology, look at gene cor-
rection, and consider some important ethical and societal im-
plications of this approach.
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Introduction
The time has come, it may be said,
To dream of many things;
Of genes—and life—and human cells—
Of Medicine—and kings—
Edward L Tatum, Perspectives in biology and medicine
1966 [1]
In 2015, Science Magazine recognized BCRISPR genome
editing^ as breakthrough of the year. Six years earlier, the
BReturn of Gene Therapy^ was recognized as a runner up,
and in 2008, the winning accolade was awarded to BCellular
Reprogramming.^ These combined technologies are not only
showing great promise but also are actually starting to deliver
on great promises. Yet they are not new; their births can each
be traced back several decades. To provide context on today’s
achievements, and perhaps to predict the forthcoming
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trajectory, it is worth considering their developmental time-
lines (summarized in Fig. 1).
In 1941, Edward Tatum and George Beadle used the fun-
gus Neurospora to arrive at their paradigmatic Bone gene one
enzyme^ hypothesis [2]; for this, they were jointly awarded
the Nobel Prize in Physiology with Joshua Lederberg in 1958.
In 1961, Marshall Nirenberg and Heinrich Matthei began to
decipher the relationship between codons and amino acids [3].
Mindful of these advances, Edward Tatum tentatively predict-
ed regenerative medicine and gene therapy:
Hence, it can be suggested that the first successful ge-
netic engineering will be done with the patient’s own
cells, for example, liver cells, grown in culture. The
desired new gene will be introduced, by directed muta-
tion, from normal cells of another donor by transduction
or by direct DNA transfer. The rare cell with the desired
change will then be selected, grown into a mass culture,
and reimplanted in the patient’s liver.
Precedents for the introduction or transfer of genes from
one cell to another exist in microbial systems and are
now being tried with mammalian cells in culture…If
this can be done successfully … it will facilitate the
development of a mammalian somatic cell genetics. It
will also bring us considerably closer to successful ge-
netic engineering [1].
The development of cell lines in the early 1960s tested the
notion that foreign DNA could be permanently and stably
introduced into mammalian cells with both functionality and
heritability. Conceptually, these studies were derived from
work on pneumococci carried out by Avery, MacLeod, and
McCarty two decades earlier, showing that DNAwas involved
in bacterial transformation [4].
It became clear by the mid-late 1960s that genetic transfor-
mation by exogenous DNA was more efficient than yet
suspected. Work on viral DNA in SV40-transformed cells
showed that viral genomes also had the capacity to be cova-
lently and stably transformed into target cells [5, 6]. These
experiments preceded the era of recombinant DNA, so it
was unclear how viruses may be modified to express or incor-
porate foreign genes and be used as therapeutic agents. Rogers
and co-workers were the first to use viruses to transfer foreign
genes into human cells [7]. However, their treatment of two
girls with hyperargininemia failed to achieve any therapeutic
outcome [8].
At this time, the first tools for recombinant DNA engineer-
ing were being assembled; the advent of mammalian genetic
modification was close, and scientists recognized the need to
define both safety and regulation [9]. A prime example of the
need to enforce this regulation was the Cline experiment in
1979, which led to the introduction of the human globin gene
into murine bone marrow cells. This partially repopulated the
bone marrow of irradiated mice with the genetically modified
marrow cells. This technique, using calcium phosphate trans-
fection, was prematurely applied on human bonemarrow cells
and transfused into two thalassemia patients in 1980. The
treatment was not successful and was done without the ap-
proval of the FDA [10, 11].
Michael Wigler and colleagues (among others) had previ-
ously used calcium phosphate transfection to deliver a frag-
ment of viral DNA containing the thymidine kinase gene into
a mouse cell line. However, this was woefully inefficient, with
successful transfection in fewer than 1 in 100,000 cells [12].
By direct intra-nuclear injection of DNA using a glass micro-
pipette, Mario Capecchi was able to improve hugely upon the
efficiency, achieving a success rate of 1 in 5 cells [13]. This set
the scene for the generation of transgenic mice, which was
achieved by four different groups within 2 years [14–17].
One of these studies demonstrated the insertion of the rabbit
β-globin gene and germ line transmission into the resulting
mouse strain [16]. This technology provided no ability to tar-
get the genomic insertions, which remained completely ran-
dom. However, Capecchi’s team noted that inserted DNA of-
ten assumed a concatemeric form, concluding this may be a
product of homologous recombination [18]. This hinted at the
prospect that it might be possible to target exogenous DNA to
specific genomic loci, which is precisely what Oliver
Smithies’ team achieved in 1988. They flanked the prospec-
tive DNA insert with sequences homologous to the human β-
globin locus and used electroporation to deliver this to a hy-
brid human cell, observing specific insertion into this locus
[19].
In 1961, the same year that Nirenberg and Matthei were
decrypting codon usage, James Till and Ernest McCulloch
first demonstrated the existence of multipotent stem cells:
bone marrow-derived cells capable of clonal expansion, colo-
ny formation, and self-renewal [20]. Two decades later,
pioneering work by Martin Evans and Matthew Kaufman re-
vealed that early mouse embryos contain pluripotent cells—
cells that have the ability to become any cell in the body
(except the placenta). This so-called cell potency was defined
when they were transplanted into blastocysts of mice of a
different strain and produced chimeric animals. By meticulous
control of isolation timing and culture conditions, they were
able to maintain these cells for the first time and observe
in vitro differentiation and teratoma formation when im-
planted into immune-deficient mice [21]. The formation of a
teratoma, which contains multiple tissue components, signi-
fied the ability of these cells to develop into more than one
germ layer. Shortly afterwards, Gail Martin generated similar
data using a teratocarcinoma feeder cell line to maintain these
stem cells. She gave these cells the name with which we are so
familiar now; Bembryonic stem cells^ [22]. In 1984, Martin
Evans and colleagues demonstrated that they could generate
germ line chimeric mice by the introduction of embryonic
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stem cells, from established lines, into mouse blastocysts be-
fore reimplantation [23].
The close of the 1980s saw accomplishment of two major
goals; firstly, Kirk Thomas and Mario Capecchi described
site-directed mutagenesis of the hypoxanthine phosphoribosyl
transferase gene in mouse embryonic stem cells using electro-
poration and homologous recombination [24]. Secondly, in
1989, Smithies and team took this technology to a natural
conclusion, by generating germ line chimeric mice derived
from embryonic stem cells which had undergone site-
directed mutagenesis using homologous recombination [25].
For a decade, the application of this technology to generate
mouse models of human disease was embraced enthusiastical-
ly by the biomedical research community. Then, in 1998, the
potential of this technology was taken to a new level, when
James Thompson and colleagues generated the first human
embryonic stem cell lines from blastocysts. These could be
maintained for months in an undifferentiated state using a
mouse embryonic fibroblast feeder line but were capable of
generating cells of endodermal, mesodermal, and ectodermal
lineages with a teratoma assay [26]. Five years later, James
Thompson and Thomas Zwaka demonstrated site-directed
mutagenesis of human embryonic stem cells using homolo-
gous recombination and electroporation [27].
One major technological stream missing from this narra-
tive, so far, has been that of viral vector-based gene transfer
technology. More than 15 years after Edward Tatum had sug-
gested that viruses could be used to deliver genetic material
Fig. 1 A flow diagram
illustrating the generation of stem
cell research, transgenesis,
genetic engineering, and gene
transfer technology. This time line
is split into three major
technology streams which
converged to establish the use of
CRISPR-Cas technology and
stem cells
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for therapeutic benefit [1], three quite different virus-based
vectors were being developed—those based on adenoviruses,
retroviruses and adeno-associated viruses (AAVs). Four
groups were involved in the construction of retroviral vectors.
They demonstrated gene delivery and genomic integration
into mammalian cells at efficiency vastly superior to non-
viral methods, such as calcium phosphate transfection and
glass pipette microinjection [28–31]. Separately, groups were
developing adenovirus-based vectors; these vectors showed
promise for highly efficient delivery, the capacity for deliver-
ing longer DNA sequences, and strong expression of the de-
sired protein [32–34]. In addition, Paul Hermonat and
Nicholas Muzyczka developed vectors based upon AAV,
which served as tools not only for the study of gene function
and regulation, but became invaluable gene therapy vectors
[35]. By 1992, numerous studies had demonstrated the deliv-
ery of therapeutically relevant human genes to rodent somatic
tissues and human gene therapy trials were being initiated. A
review article in the journal Nature entitled BHuman gene
therapy comes of age^ typified the overweening enthusiasm
of the field [36] and some advised against hyperbole, which
risked damaging the entire discipline [37].
It was 2002 before the results of the first successful human
gene therapy trial were published. Infants with X-linked se-
vere combined immunodeficiency (SCID) received autolo-
gous hematopoietic stem cell transplants; these cells had been
transduced with a retrovirus vector carrying functional com-
mon gamma chain gene. Reconstitution of immune function
was reported in four of the five patients [38]. However, the
following year, serious adverse events of leukemogenesis aris-
ing from this gene therapy were reported [39]; the field was
being viewed with increasing skepticism. Therapeutic gene
delivery required more preclinical work on vector safety,
targeting, and efficacy, and for the remainder of the decade,
this was performed in adverse financial conditions, as grant
funding and industrial recruitment flattened [40].
However, as a fundamental research tool, retrovirus vectors
were soon to prove their immense utility. A retrovirus library
of 24 transcription factor genes was used to transduce mouse
embryonic fibroblasts; these genes were each selected as
playing a potential role in stem cell pluripotency. It is testa-
ment to the transduction efficiency of this vector that simulta-
neous delivery of 24 separate genes was feasible. By with-
drawing or combining different factors, four of these were
found necessary and sufficient to revert mouse embryonic
fibroblasts to a pluripotent stem cell state. These were Oct3/
4, Sox2, c-Myc, and Klf4, also known as the Yamanaka fac-
tors [41]. Generation of the resulting induced pluripotent stem
cells (iPSCs) won, for Shinya Yamanaka, a share of the 2012
Nobel Prize in Physiology or Medicine. A year later,
Yamanaka and colleagues demonstrated that germ line trans-
genic mice could be generated from iPSCs [42]. Both his team
[43] and that of James Thomson [44] proceeded to generate
iPSCs from human fibroblasts. In 2014, the first patient re-
ceived autologous iPSCs, differentiated into retinal pigmented
epithelium, to treat age-related macular degeneration.
Numerous other clinical trials using embryonic stem cells
were becoming available from 2010 onwards (reviewed in
[45••]). The need to address the reproducibility and scaling
difficulties in iPSC production was recognized by Daniel
Paull and colleagues who developed a robotic system for der-
ivation, characterization, and differentiation of iPSCs [46].
The automation of cell production has advanced even further
as seen with the recent production of bioprinted mini-livers
from iPSCs [47].
Stem cell development has seen continuous growth and
improvement since its inception. Originally, iPSCs were gen-
erated by infecting cells with a cocktail of retroviral vectors;
since these vectors integrate into the host genome, persistent
expression of these factors and insertional mutagenesis in-
crease the risk of oncogenesis. Therefore, the means of ex-
pressing reprogramming factors for sufficient duration, in the
correct sequence, and in optimal amounts, are being devel-
oped. For example, Warren and colleagues designed synthetic
mRNA to deliver reprogramming factors transiently yet effi-
ciently [48]. Other strategies are reviewed by Singh and co-
workers [49]. It has been shown from single-cell analyses that
reprogramming consists of early stochastic and subsequent
hierarchical events [50]. More recent studies have delineated
the epigenetic changes over the course of reprogramming
[51]; the dynamics of long non-coding RNA (lncRNA) ex-
pression [52] and the interaction between microRNAs
(miRNAs) and the core reprogramming factors [53]. These,
and other such studies, will be valuable in informing how to
maximize the efficiency and safety of reprogramming.
Concurrent with these tremendous advances in stem cell
biology, gene therapy researchers were investigating multiple
strategies to improve vector safety. As with the X-SCID trial,
which led to leukemia, a second trial for Wiskott-Aldrich syn-
drome also caused leukemia in seven out of ten patients. Both
trials availed of gamma retrovirus vectors, in this case for ex
vivo hematopoietic stem cell gene therapy [54]. Gamma ret-
roviral vectors integrate in a semi-random fashion, and the
expression cassette can affect genes proximal to the insertion
sites, likely accounting for the leukemogenesis.
These previous efforts focused on the incorporation of
DNA via viral or vector-based delivery methods in order to
express a missing protein where the endogenous genome fails
to do so. In recent years, an increased understanding of nucle-
ase function has enabled more direct DNA editing. These
methods aim to restore normal gene function in situ, which
reduces the risks associated with random integration, as genes
are controlled using endogenous regulatory elements [55].
Crucially, targeted genome editing requires the double-
stranded cleavage of DNA at the genomic locus to be modi-
fied. These double-stranded breaks (DSBs) are induced by
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nucleases and can be repaired by one of two mechanisms
conserved across multiple organisms and cell types (Fig. 2):
non-homologous end-joining (NHEJ) and homology-directed
repair (HDR) [56].
Historically, gene-specific targeting has been limited to
mouse embryonic stem cells. Since the discovery of iPSCs,
many advances have been made in the field, with the success-
ful differentiation into several specific cell types and establish-
ment of patient-derived disease models [41, 57]. Establish-
ment of a specific mutation/disease model has, until
recently, relied upon traditionally low efficiency homologous
recombination protocols or upon RNA interference (RNAi)
(Table 1). Platforms such as meganucleases, zinc finger nu-
cleases (ZFNs), and transcription activator-like effector nucle-
ases (TALENs) have since been developed. These rely on
protein-based systems for nuclease-directed DSBs, effectively
inducing breaks that stimulate NHEJ or HDR at the specified
genomic locations [58]. Such developments have permitted
efficient genome editing in transformed and primary cells that
were previously thought to be out of the scope of such genetic
manipulation [59]. Indeed, TALENs have been used to effi-
ciently generate mutant alleles in human pluripotent stem cells
(hPSCs) of 15 different genes, as a means of performing dis-
ease modeling [60].
While these site-specific nuclease technologies have made
important advances in gene therapy, each has its own set of
associated advantages and disadvantages, such as cost and
difficulty of synthesis [61]. The CRISPR-Cas (short for clus-
tered, regularly interspaced, short palindromic repeats/
CRISPR-associated) technology has gained wide success in
the global scientific community, where its power as “molecu-
lar scissors” has revolutionized the prospects of genome
editing [62, 63]. Since 2012, the CRISPR-Cas system has
shown potential to satisfy the shortcomings of its predecessors
by adapting a naturally occurring mechanism from prokaryot-
ic to eukaryotic systems [64–67]. The combination of the two
powerful technologies of iPSCs and CRISPR-Cas is begin-
ning to revolutionize genetic research and boost the field of
precision medicine.
In considering the convergent stories of stem cell research,
transgenesis, genetic engineering, and gene transfer technolo-
gy, several trends emerge: (i) Each intersection of these tech-
nologies has allowed the generation of models with increasing
fidelity to the human disease; this has proved valuable both in
interrogating the underlying pathology and in the develop-
ment and testing of therapies. (ii) Genetic engineering has
improved by many orders of magnitude, in both efficiency
and precision. (iii) These technologies have transitioned from
being tools of basic research to having actual, or at least po-
tential, clinical application. (iv) Improving the safety of these
tools, in the laboratory and more recently in the clinic, has
remained an enduring imperative.
CRISPR/Cas Machinery and Mechanisms of Action
CRISPR systems, together with cas genes, are highly diverse
mechanisms of adaptable immunity used by many bacteria
and archaea to protect themselves from invading viruses, plas-
mids, and other foreign nucleic acids [68–71]. CRISPRs con-
sist of a succession of highly conserved short repeated se-
quences (23–44 bp in length) separated by similarly sized
Bspacers.^ These spacers are unique sequences usually origi-
nating from phage or plasmid DNA [72]. These adaptive sys-
tems can learn to recognize specific features of invading path-
ogens. The addition of these motifs to the host genome allows
for the recognition and destruction of subsequent invasions
Table 1 Glossary of terms
AAV
(adeno-associated virus)
A viral vector system used for gene delivery.
Chimera A single organism composed of cells from different zygotes.
Germ line therapy Insertion of DNA into germ line cells (egg or sperm) so that the
offspring will have the inserted gene.
gRNA Guide RNA.
Hematopoietic stem cells Unspecialized precursor cells that will develop into mature blood cells.
Pluripotent stem cells Stem cells that can become all cell types found in an implanted
embryo, fetus, or developed organism (excluding trophoblast and placenta).
Recombinant DNA A novel DNA sequence formed by the joining, usually in vitro, of two
non-homologous DNA molecules.
Retroviral vector A disabled RNA virus in which the viral genes have been replaced
with engineered sequences.
RuvC An endonuclease domain named for an E. coli protein involved in DNA repair.
sgRNA Single guide RNA.
Stem cells Cells with the ability to divide for indefinite periods in culture and to give
rise to specialized cells.
tracrRNA, trRNA Trans-activating crRNA.
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from genetically similar pathogens. First observed in
Escherichia coli in 1980, CRISPR loci have now been found
in 84 % of sequenced archaeal genomes and approximately
45 % of bacterial genomes [73, 74]. Their function was con-
firmed in Streptococcus thermophilus in 2007, with the dem-
onstration that resistance against a bacteriophage could be
acquired by the integration of virus fragments into the
CRISPR locus [68].
Adjacent to the CRISPRs are a set of CRISPR-associated
(cas) genes that code for proteins essential for CRISPR activ-
ity. Comparative genomics of bacterial and archaeal genomes
have suggested upwards of 45 cas gene families. The only two
of these genes present in all 45 families are cas1 and cas2; both
of which are involved in spacer acquisition [75, 76]. There are
three major types of CRISPR-Cas systems (type I, type II, and
type III), which can be further divided into ten different sub-
types. Each class contains different sets of genes, repeat pat-
terns, and species ranges.
The CRISPR/Cas system of immunity is comprised of
three steps; adaptation, expression, and interference. The
adaption stage involves the recognition and cleavage of a
protospacer from invading DNA by the cas genes. The subse-
quent insertion (acquisition) of foreign DNA (spacers) into the
CRISPR locus is also referred to as spacer acquisition or im-
munization. The expression stage refers to the expression of
relevant cas genes and their proteins leading to the transcrip-
tion of the CRISPR array into a long RNAmolecule called the
precursor CRISPR RNA (pre-crRNA). Cas proteins and other
accessory factors then process this further into short mature
crRNA. In the final interference stage, this mature crRNA and
other cas proteins recognize foreign nucleic acid and destroy
it. This is also referred to as the immunity stage, which these
mechanisms mimic [77].
Both the expression and interference stage occur differently
in each of the CRISPR systems. In type I systems, Cas6e/
Cas6f cut at the junction of single-stranded RNA (ssRNA)
and double-stranded RNA (dsRNA) formed by hairpin loops.
Trans-activating (tracr) RNAs are used in type II systems to
form dsRNA, cleaved by Cas9 and RNaseIII. Type III systems
use a Cas6 homolog in the direct repeat for cleavage and do
not require hairpin loops [74].
With each integration of invading DNA, spacer repeat units
are formed. The preference of the host to recognize and create
spacer precursors (protospacers) from specific sequences
along the invading genome is determined by the protospacer
adjacent motifs (PAMs) [78]. PAMs are short DNA sequences
(3–5 bp) that differ between the variants of CRISPR and have
been shown to be important for acquisition in type I and type
II, but not type III systems [79]. The process of spacer acqui-
sition occurs in a directional manner whereby new spacers are
preferentially added at one side of the CRISPR (the leader
sequence) [80, 81]. The leader sequence contains promoter
elements, binding sites, and elements important for spacer
integration. The cumulative addition of spacers containing
foreign nucleotide sequences therefore acts as a chronological
record of the ancestral viral invasions since protection is then
inherited by the offspring [82].
A general theme can be followed across all three systems of
CRISPR-mediated immunity. In all systems, the CRISPR lo-
cus is transcribed to generate a RNA-guide protein, Cas ribo-
nucleases process the RNA guide to form a CRISPR ribonu-
cleoprotein (crRNP) complex. This leads to the formation of a
long primary transcript, known as the pre-crRNA, which can
contain secondary structures, called hairpins, if palindromic
sequences exist within the CRISPR sequence. These pre-
crRNA sequences are then processed into smaller units, which
correspond to the spacer and repeats regions [83].
In August 2012, Jennifer Doudna and Emmanuelle
Charpentier co-authored a key study demonstrating the tech-
nical potential of CRISPR-Cas to cut and splice genes with
extreme ease and efficiency [84]. Due to its high degree of
fidelity and comparatively simple construction, CRISPR-Cas
is now widely used in genome editing. CRISPR-Cas genome
editing is a type II CRISPR system; this system includes Cas9,
crRNA, trans-activating crRNA (tracrRNA), and two template
options for DNA repair; non-homologous end joining (NHEJ)
or homology directed repair (HDR). Two nuclease domains
confer cleavage ability to Cas9: the HNH domain cleaves the
complementary DNA strand and the RuvC-like domain
cleaves the non-complementary strand [77]. A simple illustra-
tion of this is provided in Fig. 2.
To date, every facet of the CRISPR-Cas system has been
altered and improved in terms of its technical application.
Starting with improved endonuclease function, an alternative
to Cas9, called Cpf1, was discovered in the bacterial genera
Prevotella and Francisella. Interestingly, Cpf1 is a single
RNA-guided enzyme that does not require tracrRNA and gen-
erates staggered DSBs with a 4–5-nt overhang distal to a 5′ T-
rich PAM [85••]. Firstly, Cas9 in its natural form requires two
RNAs and generates cleavage products with blunt ends, which
are less easy to work with, as DNA sequences could insert in
either end. Cpf1, however, makes staggered cuts that generate
a 5′ overhang, which improves the precision of DNA inser-
tions. Secondly, unlike Cas9, Cpf1 cuts at a site distal to the
gene, preserving the seed region. This is essential for target
recognition if future editing is required. Thirdly, because Cpf1
is smaller and does not require a tracrRNA, it may be easier to
deliver to cells.
Application of CRISPR-Cas in Genome Editing
The therapeutic potential of CRISPR-Cas has already been
demonstrated in many instances. Cas9 has been applied im-
munologically as an antimicrobial agent and has been devel-
oped to specifically target antibiotic resistant in highly virulent
strains of bacteria [77, 86]. Gene therapy applications have
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also been demonstrated for monogenic diseases. Cells from
human patients with cystic fibrosis showed functional repair
of the CFTR gene in vitro in cultured intestinal stem cell
organoids using CRISPR-Cas [86]. The defective gene caus-
ing hereditary tyrosinemia was corrected in mice after hydro-
dynamic injection of CRISPR components. This led to an
expansion of mutation-corrected hepatocytes in vivo and re-
sulted in a rescued phenotype in adult mice [87]. Advancing
from therapeutic treatment, as described, to preventative tech-
niques, muscular dystrophy was prevented when germ line
mediated editing of mice with Duchennemuscular was carried
out [88].
The treatment of viral infections such as HIV and
hepatitis B [89] has also been demonstrated using
Cas9. In the first instance, iPSCs were generated, and
through genome editing, were made to be homozygous
for a mutation, which confers HIV-1 resistance. In this
study, wild-type iPSCs were modified using TALENS
and CRISPR-Cas [90, 91••].
An important milestone, was the first genetic modifications
to be carried out in primate embryos. Here, CRISPR was
carried out in one-cell embryos to successfully generate mod-
ified cynomolgus monkeys [92]. This is the closest of the
animal models in similarity to humans and can give evidence
for how the system might behave in human embryos. This
could be used to potentially prevent non-complex hereditary
diseases, such as single gene defects. However, without full
predictability of the off-target effects, germ line gene editing
remains ethically and scientifically unsafe.
In terms of delivery, the CRISPR-Cas system has been
directly applied to human cells by co-delivery of plasmids that
encode Cas9 expression together with the necessary crRNA
components [64, 93]. Recent identification of smaller Cas
proteins may enable and enhance the combination of this tech-
nology with vectors that have gained increasing success for
their safety profile and efficiency, such as AAV vectors [94].
Due to their relatively low immunogenicity, AAVs are com-
monly chosen for in vivo gene delivery for in somatic gene
therapy [95].
Advantages, Disadvantages, and Potential Applications
Themain advantages of the CRISPR-Cas system are its ability
to genetically modify an organismwithout leaving any foreign
DNA behind and its versatility and simplicity of program-
ming. Unlike the reprogramming of its predecessors, ZFNs
and TALENs, which require editing of DNA-interacting do-
mains located at different sites on the DNA-binding scaffolds,
CRISPR-Cas systems changes are only executed on the re-
combinant RNA sequences [62, 96]. Ease of use, low cost,
high speed, multiplexing potential, and equal or higher specif-
ic DNA targeting ability have secured its popularity and suc-
cess across the global scientific community [65, 96, 97].
Gupta and colleagues provide a useful review comparing
ZFN, TALEN, and CRISPR-Cas technologies [98].
Nevertheless, as for many other emerging technologies,
delivery of the CRISPR-Cas components to the target cells
remains one of the main issues [63]. The limited DNA pack-
aging capacity of AAV vectors, however, is being addressed
with the development of shorter gRNA-coding sequences and
the identification of smaller Cas endonucleases, as mentioned
above. A second problem concerns the number of program-
mable bases in Cas9, which is limited to 20 and whose spec-
ificity is subject to the PAM sequence’s position: if this is not
within ten bases from the base target, the targeting frequency
is greatly diminished [63, 96]. This issue is being addressed by
Fig. 2 An illustration of genome
editing with CRISPR-Cas9. The
knock-out approach results in a
loss of function of the target DNA
double strand breaks by non-
homologous end-joining. The
knock-in results in an insertion at
the repair site which exploits
endogenous homology-directed
repair
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extending the PAM preferences of Cas9 and identifying new
CRISPR endonucleases [85••, 99]. The concerns over Cas9
re-cutting after successful introduction of the desired modifi-
cation may be solved by exploitation of synthetic CRISPR
RNAs (scrRNAs): these offer controlled silencing options
through natural decay of the scrRNA itself, injection of a
Bsponge^ sequence complementary to the scrRNA or
tracrRNA, or injection of another scrRNA directed against
the Cas9 gene [97]. Principle concerns that remain are the
insufficient target specificity and the potential for off-target
events, which are difficult to prevent and may be undetectable
for current low-cost broadly used tools as well as for more
expensive and less accessible whole-genome sequencing
[100••]. In particular, an emergence of tools for the prediction
of off-target events and gRNA design has ensued—these are
reviewed by Graham and Root [87]. The latest development
of a modified Cas9 variant shows remarkably fewer off-target
effects while retaining full site-specific activity and illustrates
the ample scope for the optimization of the system. Here, use
of a SpCas9-HF1 (for high-fidelity) variant resulted in the
occurrence of off-target events undetectable by genome-
wide break capture and targeted sequencing methods [101].
Besides these practical aspects, the major drawback the
CRISPR-Cas system faces is restrictive legislation. The power
of this gene-editing tool has caused concerns to wider society,
due to the potential for irrevocable alteration of future gener-
ations, if used in germ line modifications.
Ethical Considerations and Conclusions
Concerns about the genetic alteration of the human species
from both the scientific and lay community started to rise
slowly but progressively after the advent of recombinant
DNA technology [102]. The call for the recent International
Summit of Genome Editing in Washington 2015 echoes that
of the first Asilomar conference in 1975. Both called for a
moratorium on experiments due to fear that the technologies
would be used for experiments which lift the ethical threshold
with the potential to alter human evolution.
With the rapid advancement of CRISPR-Cas systems to-
wards application the for treatment of diseases such as
Duchenne muscular dystrophy, hemoglobinopathies, Leber
congenital amaurosis, and HIV infection, ethical implications
are now being discussed [63]. In particular, the first report on
the use of CRISPR-Cas9 on human tripronuclear zygotes was
published in 2015. These zygotes have one oocyte nucleus
and two sperm nuclei and are therefore unable to develop into
viable embryos. It was this work that prompted a worldwide
moratorium by both biologists and ethicists on human germ
line genetic engineering [103]. Although this study showed
low homologous recombination events of the humanβ-globin
(HBB) gene, for which the CRISPR-Cas9 system was de-
signed, as well as mosaicism and off-target cleavage at various
sites, it was the first time CRISPR-Cas9 effectively cleaved
endogenous genes on human embryos [104••]. It was pro-
posed that dynamic guidelines, involving the wider society,
should evolve with the progression of the scientific knowl-
edge and should be established rather than imposing a mora-
torium on the advancement of such a promising technology
[105]. This announcement was in keeping with a previous
statement by the Hinxton Group, that concerns on possible
human applications of these techniques should not inhibit
the advancement of scientifically defensible basic research,
especially as this very research will be the key to gaining such
knowledge [106]. It did agree that human embryos or germ
line cells subject to gene editing should not be used to estab-
lish pregnancies and produced a list of the current technical
and moral issues, upon resolution of which, clinical somatic
and germ line applications could be envisaged to eradicate
devastating inheritable diseases [105]. Fear that one of
CRISPR-Cas’ major advantages, its power for “democratiza-
tion of gene targeting” [107] could be dangerous if used by the
wrong people to Benhance^ population minorities and reignite
an interest for eugenics, maybe addressed by strong interna-
tional jurisdictions and global public engagement [105, 106,
108]. However, before this could be performed, a deeper un-
derstanding of appropriate models (both cellular and animal,
as well as human embryonic stem/iPS cell-derived germ line
cells) to test efficacy and safety and multigenerational effects,
and optimization of genome editing tools to minimize off-
target events will be warranted. These include the develop-
ment of more accurate and sensitive tools to assess off-target
events and mosaicism [106]. Moreover, the types of cells and
embryos that may be used in this context vary broadly and
they need to be clarified to both the scientific and lay commu-
nity to allow for constructive progression.
Non-viable preimplantation embryos from in vitro fertili-
zation clinics may not satisfy the criterion of scientific validity,
as the endogenous DNA repair mechanisms in their cells may
be altered, but also raise ethical issues. Viable, unused embry-
os from these clinics would technically bemore suitable; how-
ever, it could display high levels of mosaicism. Embryos spe-
cifically designed for research would be the most valuable in
terms of research, but are the most ethically bound source of
research material [106]. When considering such aspects, it
should be kept in mind that human germ line editing may be
the only solution to cure genetic diseases that manifest before
birth and systemically (e.g., cystic fibrosis) in only one but
very predominant tissue (e.g., muscular dystrophy) or in not
easily accessible tissues (e.g., basal ganglia in Huntington’s
disease). Patient-advocacy groups put hope in the use of these
novel alternatives [109]. Concerns have further been
expressed about the polygenic control of many human traits,
the current difficulty to predict short-term effects of a genetic
mutation and its side effects, as well as the apparent impossi-
bility to anticipate its long-term effects in a putative future
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environment. To some, these points indicate that the hope to
definitively eradicate human genetic diseases is only an illu-
sion [110].
Unlike other moments in scientific history, the CRISPR-
Cas system has opened an era of changes, which may span
from groundbreaking therapeutic applications to daunting
fears of irreversible perturbation of human evolution. It is
essential that broad informed discussion across all exponents
of society continue, to find a balance that will progressively
lead to a society pivoted on the prioritization of human well-
being and human rights.
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